--- a
+++ b/clusters/3009knumclusters/clust_57.txt
@@ -0,0 +1,622 @@
+Normal baseline cardiac ejection fraction >= 50%
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by echocardiogram or radionuclide angiogram
+If cardiac function assessment is clinically indicated or performed: participants will be ineligible if left ventricular ejection fraction (LVEF) is less than normal per institutional guidelines, or < 55%, if the threshold for normal is not otherwise specified by institutional guidelines
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
+Ejection fraction of >= 50% by gated radionuclide study
+Patients who have had an echocardiogram performed within 6 months prior to step 2 randomization must have ventricular ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% or >= within normal limits for the institution
+Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by radionuclide angiogram
+Shortening fraction of >= 27% or
+Ejection fraction of >= 50%
+Ejection fraction of >= 50% by radionuclide angiogram
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
+Ejection fraction of >= 50% by radionuclide angiogram
+Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
+Patients must have ejection fraction >= 45% based on echocardiogram performed within 28 days prior to registration
+Adequate Cardiac Function defined as: Shortening fraction of ? 27% by echocardiogram, or Ejection fraction of ? 50% by radionuclide evaluation or echocardiogram.
+Left ventricular (LV) ejection fraction <50%, evaluation based on the institutional lower limit of normal.
+Patients with angina, a cardiac ejection fraction < 50%, or ischemic heart disease are not eligible
+Participants with known congestive heart failure (CHF); if known, patients with left ventricular ejection fraction (LVEF) =< 40% are excluded
+All included patients must have normal cardiac function as defined by an ejection fraction of >= 50% and no decrease in wall motion by echocardiogram
+Left ventricular ejection fraction < 50%
+Cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if the patient is > 50 years of age, or history of cardiac disease or anthracycline exposure; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
+History of myocardial infarction =< 6 months, current symptomatic CHF or left ventricular ejection fraction (LVEF) < 40% or > grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
+History of ejection fraction drop below the lower limit of normal with trastuzumab and/or pertuzumab.
+Transthoracic echocardiogram with ejection fraction > 50%
+Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by echocardiogram =< 28 days prior to registration
+Left ventricular ejection fraction (LVEF) ?50%. A lower LVEF (?40%) is permissible if a formal cardiologic evaluation reveals no evidence for clinically significant functional impairment, otherwise the subject may not enter the study.
+Ejection fraction of >= 50% by gated radionuclide study (while not receiving medications for cardiac function)
+Subject must have a left ventricular ejection fraction of ? 50%;
+Left ventricular ejection fraction (LVEF) less than the lower limit of normal (LLN) as assessed by echocardiography
+Baseline left ventricular ejection fraction (LVEF) below the lower limit of normal (LLN) or < 55% measured by echocardiography or institution’s lower limit of normal (LLN) for MUGA
+Left ventricular ejection fraction (LVEF) < 45%
+All included subjects must have normal cardiac function as defined by an ejection fraction of > 50% by echocardiogram
+Left ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO)
+Left ventricular ejection fraction greater than or equal to (>=) 50 percentage (%); >=55% (cohort E only)
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)
+Left ventricular ejection fraction >= 35%, or shortening fraction > 25% (for pediatric patients, a normal ejection fraction is required)
+Left ventricular ejection fraction >= 50%
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
+Left ventricular ejection fraction > 50%.
+Participants must have a left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction of < 45%
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) (per institutional normal) determined by echocardiogram or nuclear medicine scan, within 30 days of registration
+Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or <50%, whichever is lower Infections Patients who meet any of the following infection exclusion criteria will be excluded from study entry:
+Adequate cardiac function as assessed by cardiac troponin I within normal range; left ventricular ejection fraction ? 50% or institutional lower limit of normal; cumulative anthracycline dose <360 mg/m2 doxorubicin or equivalent.
+Left ventricular ejection fraction > 45% (in children, shortening fraction > 26%)
+Left ventricular ejection fraction >= 40% or shortening fraction >= 25%
+Left ventricular ejection fraction (LVEF) >= 45%
+Participants must have a left ventricular ejection fraction (LVEF) >= 50%
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
+Left ventricular ejection fraction (LVEF) greater than (>) 50 percent (%) or above the lower limit of the institutional normal range, whichever is lower
+Left ventricular ejection fraction (LVEF) < 50%, regardless of whether there are symptoms of heart failure
+Cardiac function: Ejection fraction > 40%
+Left ventricular ejection fraction < 40%
+INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) within 4 weeks of registration
+Participant has left ventricular ejection fraction at rest ? 40%.
+Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or below 50% Central Nervous System (CNS) Exclusion Criteria:
+Patients must have adequate cardiac function as defined as:\r\n* Shortening fraction of ? 27% by echocardiogram, or\r\n* Ejection fraction of ? 50% by radionuclide angiogram
+Ejection fraction < 55% or less than the lower limit of normal of the institutional standard.
+Participants with clinically significant arrhythmias, complex congenital heart disease, or left ventricular ejection fraction (LVEF) <50 percent (%) or shortening fraction (SF) <=28%
+Subject has a documented left ventricular ejection fraction > 50%
+Ejection Fraction >= 45%
+Abnormal left ventricular ejection fraction (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower).
+Cardiac: left ventricular ejection fraction at rest must be ? 45%
+Left ventricular ejection fraction (LVEF) ?55% (or the institutional lower limit of normal [LLN]) as evidenced on ECHO.
+Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or below 50 percent (%), whichever is lower General Exclusion Criteria
+Left ventricular ejection fraction >= 45% or fractional shortening >= 28%
+Ejection fraction >= 45%
+Cardiac ejection fraction < 45%
+Cardiac ejection fraction < 35%
+Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
+Systolic cardiac function will be assessed at screening if clinically indicated by history and physical; only patients with left ventricular ejection fraction (LVEF) >= 50% will be eligible for enrollment
+Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%
+Left ventricular ejection fraction < 40%, symptomatic coronary artery disease, or uncontrolled arrhythmias
+PART I: Baseline left ventricular ejection fraction (LVEF) by 2 dimensional (2D) echocardiogram >= 53%
+Left ventricular ejection fraction (LVEF) within normal institutional limits
+Within 4 weeks prior to study enrollment: Ejection fraction of >= 50% by radionuclide angiogram
+Cardiac ejection fraction >= 50% as determined by screening echocardiogram
+Echocardiogram demonstrated left ventricular ejection fraction >= 40%.
+Left ventricular ejection fraction > 50%
+Left ventricular ejection fraction (LVEF) > 45%
+Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
+Left ventricular ejection fraction < 40% as measured on transthoracic echocardiogram
+Patients with impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
+Left ventricular ejection fraction > 45% or shortening fraction > 26%
+TREATMENT WITH SJCAR19: Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
+Left ventricular ejection fraction (LVEF) (echocardiogram [echo]) >= lower limit of normal (LLN).
+Cardiac: Asymptomatic or if symptomatic, then left ventricular ejection fraction (LVEF) at rest must be >= 40% and must improve with exercise.
+Adequate cardiac function defined as shortening fraction of ? 27% or ejection fraction ? 45%
+Left ventricular ejection fraction >= 40%.
+Baseline cardiac ejection fraction must be >= 40 %.
+Left ventricular ejection fraction of at least 45% by either echocardiography or radionucleotide angiography
+Known left ventricular ejection fraction (LVEF) < 40%. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF 40%?50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
+Patients who have a left ventricular ejection fraction (LVEF) < 45% at screening.
+Left ventricular ejection fraction ? 45% or fractional shortening ? 28%, and no clinically significant electrocardiogram (ECG) findings
+Left Ventricular Ejection Fraction (LVEF) >/=50% HER2-Expressing Breast Cancer-Specific Inclusion Criteria
+Must have left ventricular ejection fraction > 50%
+Left ventricular ejection fraction >= 50%.
+Cardiac ejection fraction of >= 45%
+STRATUM B: Participants with abnormal left ventricular ejection fraction (LVEF) on screening, defined as > 10% below lower limit of normal
+Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction (LVEF) < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate, to be eligible
+Left ventricular ejection fraction (LVEF) >= 50%;
+Decreased cardiac function as evidenced by a left ventricular ejection fraction of < 45%
+Any patient known to have an left ventricular ejection fraction (LVEF) =< 45 percent (%)
+Baseline left ventricular ejection fraction value <50% or shortening fraction of <27%
+Has a left ventricular ejection fraction (LVEF) ?50% by either an ECHO or MUGA within 28 days before registration
+Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
+Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or <50%, whichever is lower
+Uncontrolled cardiac disease, or myocardial infarction within the last 12 months, or left ventricular ejection fraction (LVEF) < 50%, or QTcF interval > 470 msec
+Within two weeks prior to enrollment: Left ventricular ejection fraction (LVEF) >= 50% as determined an echocardiogram
+Left ventricular ejection fraction (LVEF) >= 55%
+No uncontrolled or severe cardiac disease. Baseline ejection fraction (by nuclear imaging or echocardiography) must by ? 50%
+Left ventricular ejection fraction (LVEF) >= ULN (institutional limit)
+Cardiac ejection fraction of >= 45%
+Cardiac: left ventricular ejection fraction < 35%
+Left ventricular ejection fraction > 40%
+Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
+Left ventricular ejection fraction (LVEF) of >= 40%
+Left ventricular ejection fraction (LVEF) >= 45%
+Have left ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to enrollment.
+Symptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 40%, symptomatic coronary artery disease or symptomatic arrhythmias
+Left Ventricular Ejection Fraction (LVEF) < 50%, or a history of clinically significant decrease in LVEF during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;
+Organ dysfunction\r\n* Cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist\r\n* Pulmonary: \r\n** Diffusing capacity of the lungs for carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in the first second of breath (FEV1) < 40% and/or receiving supplementary continuous oxygen\r\n** The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules
+Ejection fraction of >= 55% by gated radionuclide study
+Left ventricular ejection fraction < 50% or institutional lower limit of normal, whichever is lower
+Abnormal left ventricular ejection fraction on echocardiography or MUGA (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower).
+Left ventricular ejection fraction > 30%
+Known cardiac ejection fraction of > or = 45% within the past 3 months
+Echocardiogram demonstrating left ventricular ejection fraction (LVEF) >= 35%
+Left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction < 35%
+History of congestive heart failure and/or an left ventricular ejection fraction (LVEF) < 40%
+Left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction (LVEF) ejection fraction (EF) >= of 50% (by echocardiogram or MUGA scan within 12 weeks of registration), within 2 weeks of registration (except where specified otherwise)
+Left ventricular ejection fraction (LVEF) >= lower limit of institutional normal as assessed by echocardiography
+Left ventricular ejection fraction (LVEF) < institutional lower limit of normal or < 50%
+Left ventricular ejection fraction of > 40%.
+Left Ventricular Ejection Fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)
+Ejection fraction > 45%
+History of congestive heart failure and cardiac ejection fraction =< 40%
+Left ventricular ejection fraction (LVEF) of >= 50%
+FULL STUDY INCLUSION CRITERIA: Left ventricular ejection fraction (LVEF) >= 50% or the lower limit of normal (LLN) according to local institution ranges of normality
+Left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 40 percent (%)
+Left ventricular ejection fraction (LVEF) <50% at screening.
+Adequate cardiac function with left ventricular ejection fraction >= 40%. No uncontrolled arrhythmias or symptomatic cardiac disease
+Patients with left ventricular ejection fraction (LVEF) < 40%
+Cardiac ejection fraction >= 50%
+Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
+Any of the following:\r\n* Correct QT (QTc) prolongation (defined as a QTc interval >= 500 msecs)\r\n* Left ventricular ejection fraction (LVEF) < institutional lower limits of normal (LLN)\r\n* Frequent ventricular ectopy\r\n* Evidence of ongoing myocardial ischemia
+Left ventricular ejection fraction < 35%
+Cardiac ejection fraction at rest must be >= 40%
+Left ventricular ejection fraction (LVEF) > 40%
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) (institutional limit)
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN)
+Abnormal left ventricular ejection fraction on echocardiography (less than the lower limit of normal for a patient of that age at the treating institution or < 45%)
+Have a 2-dimensional (2D) echocardiogram with left ventricular ejection fraction = or > 45% in order to receive epirubicin; subjects with inadequate ejection fraction (EF) or other contraindication can proceed on study without the use of epirubicin
+Left ventricular ejection fraction >= 35%
+Ejection fraction less than 40% by echocardiography
+Cardiac left ventricular ejection fraction >= 50% at rest
+Left ventricular ejection fraction >= 50%
+Adequate cardiopulmonary reserve defined as follows as assessed within 4 months of study entry:\r\n* Predicted postoperative forced expiratory volume FEV1 > 1L\r\n* Normal left ventricular function (ejection fraction EF ? 45%) and right ventricular function\r\n* No pulmonary hypertension noted on preoperative transthoracic echocardiography
+Left ventricular ejection fraction (LVEF) ? 50%
+Participants must have normal cardiac ejection fraction (per label, as defined as institutional normal)
+Left ventricular ejection fraction at or above institutional lower limits of normal (by echocardiogram within 12 weeks of registration)
+Must have left ventricular ejection fraction >= 50%
+Must have left ventricular ejection fraction > 50%
+Left ventricular ejection fraction >= 40%
+Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
+Ejection fraction >= 40%
+Left ventricular ejection fraction (LVEF) >= 45%
+Left ventricular ejection fraction < 50%
+Ejection fraction > 50% by echocardiogram or radionuclide study
+Adequate cardiac function with left ventricular ejection fraction (LVEF) ? 55% at baseline.
+Shortening fraction >= 28% or ejection fraction (LVEF) >= 55%, as well as
+Left ventricular ejection fraction of at least 40% (myeloablative regimen 1, reduced intensity regimen 3)
+Left ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)
+Have adequate cardiac function as assessed by echocardiogram, with an ejection fraction (EF) > 45%
+Significant cardiovascular abnormalities as defined by any one of the following: congestive heart failure, clinically significant hypotension, symptomatic coronary artery disease, or a documented ejection fraction of < 45%; any patient with an ejection fraction (EF) of 45-49% must receive clearance by a cardiologist to be eligible for the trial
+Patients with left ventricular ejection fraction < 50% or 10% decrease from baseline on echocardiogram after anthracycline based chemotherapy
+Left ventricular ejection fraction (LVEF) below 45% or lifetime exposure to anthracyclines over 350mg/m2 of daunorubicin equivalent
+Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 35%
+Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] greater than or equal to 50%)
+Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] >/= 45%)
+Left ventricular ejection fraction >= 40%
+Adequate cardiac function with a left ventricular ejection fraction >= 40%
+Left ventricular ejection fraction (LVEF) ? 50%
+Shortening fraction >= 27% or ejection fraction >= 50%, no clinical congestive heart failure
+Adequate cardiac function with left ventricular ejection fraction >= 40%
+Systolic heart failure defined as left ventricular ejection fraction =< 45%
+Subjects must have a left ventricular ejection fraction (LVEF) of >= 45%
+Cardiac ejection fraction (EF) < 40%
+History or presence of heart failure or left ventricular dysfunction with ejection fraction < 40% within the previous 6 months; if >6 months cardiac function within normal limits and free of cardiac-related symptoms
+LVEF (left ventricular end diastolic function) of >= 45%; LVEF between 45% and 54% must have negative stress test with increase in ejection fraction (EF) of 3-5 points with stress
+Adequate cardiac function defined as an ejection fraction > 50% or shortening fraction >= 27%.
+Left ventricular ejection fraction (LVEF) >= 45%; LVEF assessment must have been performed within 8 weeks of enrollment
+Baseline ejection fraction must be >= 40%
+ECHO shortening fraction ? 27%
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study within 7 days prior to enrollment
+Congestive heart failure (NYHA class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment
+Echocardiogram must have a shortening fraction or an ejection fraction greater than institutional lower limit of normal for age and gender; echocardiogram must be obtained while patient is not receiving cardiotropic medications (eg., pressors or afterload reducers)
+Adequate cardiac function with left ventricular ejection fraction >= 40%
+Shortening fraction of >= 28% or an ejection fraction >= 50%
+The subject has a documented left ventricular ejection fraction > 50%
+Left ventricular ejection fraction (LVEF) assessed by echocardiogram within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%
+Baseline test of ejection fraction must be >= 50%
+Left ventricular ejection fraction (LVEF) >= 40% on ECHO or MUGA
+Normal cardiac function must be documented within 90 days prior to registration; result of ejection fraction must be above the normal limit of the institution
+Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) greater than or equal to 50%) at baseline as determined by echocardiography.
+Ejection fraction < 30%, or uncontrolled cardiac failure
+Adequate cardiac function defined as: normal 12 lead electrocardiogram (EKG) with corrected QT interval (QTc) < 450 msec, and either shortening fraction of >= 28% by echocardiogram and qualitatively normal left ventricular function, or ejection fraction of >= 55% by echocardiogram
+Shortening fraction >= 27% or left ventricular ejection fraction >= 50% by echocardiogram within the past 1 year prior to registration
+Left ventricular ejection fraction equal to or greater than normal within 1 month of enrollment; echocardiography (ECHO) scans must be used throughout the study
+Left ventricular ejection fraction ? 45%
+Left ventricular ejection fraction > 45%
+Adequate cardiac and pulmonary function; patients with decreased left ventricular ejection fraction (LVEF) =< 40% or diffusion capacity of carbon monoxide (DLCO) =< 50% of predicted will be evaluated by cardiology or pulmonary prior to enrollment on this protocol; patient with left ventricular assist device (LVAD) placement without heart failure symptoms will be allowed
+Ejection fraction > 50%
+Left ventricular ejection fraction (LVEF) > 40%
+PART 2: Left ventricular ejection fraction > 40% OR
+PART 2: Shortening fraction > 26%
+Left ventricular ejection fraction (LVEF) >= 40%
+Left ventricular ejection fraction (LVEF) < 50% (evaluated by echocardiogram or magnetic resonance imaging [MRI])
+Patients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled arrhythmia); if the patient's cardiac history is questionable, a measurement of left ventricular ejection fraction should be obtained within 42 days prior to registration; patients with left ventricular ejection fraction < 50% are not eligible
+Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution's lower limit of predicted normal.
+Left ventricular ejection fraction < 35%
+Left ventricular ejection fraction at rest must be >= 35%
+Known cardiac ejection fraction < 50%
+Symptomatic uncontrolled coronary artery disease or ejection fraction < 40%
+Known cardiac ejection fraction of >= 45% within the past 6 months
+Left Ventricular Ejection Fraction (LVEF) ? 50%.
+Left ventricular ejection fraction must be evaluated by nuclear medicine scan or echocardiography and measure >= 50%
+Left ventricular >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) ejection fraction
+Baseline left ventricular ejection fraction (LVEF) >= 40%
+Left ventricular ejection fraction at least 45% on appropriate medical therapy; no uncontrolled arrhythmias or symptomatic cardiac disease
+Left ventricular ejection fraction >= 45%
+Left ventricular ejection fraction: < 40% estimated by echocardiogram (ECHO)
+Patients with significant lung disease, an ejection fraction less than 40%, or a resting heart rate less than 60/min will not be enrolled
+Left ventricular ejection fraction equal or greater than 40%
+Ejection fraction >= 35%
+RECIPIENT: Left ventricular ejection fraction > 40%, preferably by 2-dimensional (2-D) echocardiogram (echo) obtained within 28 days of enrollment
+Ejection fraction >= 45% on echocardiogram
+Left ventricular ejection fraction >= 45%; no uncontrolled arrhythmias or uncontrolled symptomatic cardiac disease
+Patients with symptomatic coronary artery disease, uncontrolled congestive heart failure; left ventricular ejection fraction is not required to be measured, however if it is measured, patient is excluded if ejection fraction is < 30%
+Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
+Left ventricular ejection fraction at rest must be >= 35%, or shortening fraction > 25%
+Cardiac left ventricular ejection fraction (LVEF) > 45%
+Left ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or uncontrolled symptomatic cardiac disease
+Left ventricular end diastolic function (LVEF) of >= 50%
+Left ventricular ejection fraction greater than 40%
+Left ventricular ejection fraction (EF) >= 45%
+Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrhythmias or symptomatic heart disease
+Asymptomatic or if symptomatic then left ventricular ejection function (LVEF) at rest must be >= 50% and must improve with exercise
+Any patient known to have left ventricular ejection fraction (LVEF) =< 45%
+Left ventricular ejection fraction (LVEF) ? 50% of the lower limit of normal (LLN) according to local institutional ranges
+Cardiac ejection fraction =< 50%
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by gated radionuclide study
+Left ventricular end diastolic function (LVEF) of >= 50%
+Left ventricular ejection fraction (LVEF) of >= 45%
+Left ventricular ejection fraction >= 35%, or shortening fraction > 25%, unless cleared by a cardiologist
+Left ventricular shortening fraction (LVSF) less than 25%
+Left ventricular ejection fraction > 40%, preferably by two dimensional (2-D) echocardiogram (ECHO), obtained within 90 days of enrollment; if the patient has radiological evidence of aortic, renal artery, or coronary artery vasculitis, a left ventricular ejection fraction > 30% is acceptable
+Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exercise
+Left ventricular ejection fraction at rest must be >= 35%
+Symptomatic coronary artery disease or ejection fraction < 40% or other cardiac failure requiring therapy (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if the patient has a history of anthracyclines or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
+LVEF (left ventricular ejection fraction) >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
+Normal echocardiogram (ECHO) (Left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)
+Left ventricle ejection fraction (LVEF) >= 30%
+Ejection fraction below the lower limit of normal (< 50%)
+Adequate cardiac function defined as absence of decompensated congestive heart failure or uncontrolled arrhythmia AND left ventricular ejection fraction >= 35% OR fractional shortening > 22%
+Left ventricular ejection fraction > 50%
+Adequate cardiac function defined as absence of decompensated congestive heart failure, or uncontrolled arrhythmia and:\r\n* Left ventricular ejection fraction >= 35% or\r\n* Fractional shortening > 22%
+Shortening fraction > 24% by echocardiogram, or ejection fraction > 30% by radionuclide angiogram
+Ejection fraction >= 45%
+Left ventricular ejection fraction < 35%
+Left ventricular ejection fraction (LVEF) >= 45%
+Cardiac: ejection fraction > 45%
+Left ventricular ejection fraction >= 45%
+Has cardiac pathology: Participants with known congestive heart failure, symptomatic or left ventricular (LV) ejection fraction <50% or shortening fraction <27% and participants with congenital long QT syndrome, bradyarrhythmias, or QTc >480 msec on at least 2 separate electrocardiograms (ECGs).
+Left ventricular ejection fraction (LVEF) <40%
+Cardiac-left ventricular ejection fraction < 40%, symptomatic coronary artery disease, or uncontrolled arrhythmias
+Has Left Ventricular Ejection Fraction ? 50%
+Left ventricular ejection fraction (LVEF) >= 45% as measured by echocardiogram during screening evaluation
+Cardiac ejection fraction ? 50%. If between 40-49% a cardiology consult is required
+Cardiac ejection fraction > 30%
+Left ventricular ejection fraction greater than 45%
+Ventricular ejection fraction (VEF) =< 55% at baseline
+Stable cardiac condition with a left ventricular ejection fraction of 40% or greater.
+Left ventricular ejection fraction > 45%
+Adequate cardiac function defined by a left ventricular ejection fraction (LVEF) ?40%, QTc <450 msec, and no evidence of clinically significant dysrhythmias on ECG
+Cardiac ejection fraction less than 40%
+Left ventricular ejection fraction (LVEF) equal to or above the lower limit of normal (LLN) at the institution.
+Left ventricular ejection fraction (LVEF) > 45%
+Cardiac left ventricular ejection fraction (LVEF) > 45%
+Known history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmias
+Left ventricular ejection fraction less than 50%
+Left ventricular ejection fraction at rest > 40% within 3 months of registration.
+Left ventricular ejection fraction >= 50% OR
+Shortening fraction > 26%
+Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction ? 40%
+Patients must have a left ventricular ejection (LVEF) >= 50% within 56 days of enrollment
+Left ventricular ejection fraction (LVEF) >= 40%, no uncontrolled arrhythmias or symptomatic cardiac disease.
+Known cardiac ejection fraction of >= 45% within the past 3 months
+Measurement of left ventricular ejection fraction (LVEF) should be performed in patients with prior anthracycline exposure or known history of arrhythmia or structural heart disease; in these cases, LVEF must be >= 40%
+Normal left ventricular ejection fraction, as defined by ejection fraction (EF) >= 50%
+Left ventricular ejection fraction (LVEF) > 50%
+Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower Phase Ib Dose-Escalation Arm B (Venetoclax and Idasanutlin): Received the following within 7 days prior to the initiation of study treatment:
+Patients must have a cardiac ejection fraction of >= 40%, or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a 2-D ECHO scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to allogeneic transplantation
+Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
+Left ventricular ejection fraction (LVEF) </= 40 percent (%) at screening
+Shortening fraction >= 28% by echocardiogram or ejection fraction >= 50% by echocardiogram or radionuclide study
+Left ventricular ejection fraction >= 45%
+Left ventricular ejection fraction (LVEF) >= 50%
+Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
+Cardiac insufficiency: left ventricular ejection fraction (LVEF) < 50% or coronary artery disease requiring treatment
+Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50%
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
+Left ventricular ejection fraction > 40% (within 28 days of treatment start)
+Cardiac ejection fraction >= 45%
+Symptomatic congestive heart failure or radionuclide ventriculogram (RVG) or echocardiogram determined left ventricular ejection fraction of < 30%, active angina pectoris, or uncontrolled hypertension
+Left ventricular ejection fraction below the lower limit of normal
+Within 30 days of registration: Left ventricular ejection fraction (echocardiogram within 6 months permitted) >= 40%
+Left ventricle ejection fraction (LVEF) >= 55%, specimens must be collected within 10 days prior to the start of study treatment
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
+Ejection fraction >= 47% by radionuclide angiogram
+Left ventricular ejection fraction at rest >= 40%
+Adequate cardiac reserve (ejection fraction [EF] >= 50%)
+Cardiac ejection fraction has to be >= 50%
+Left ventricular ejection fraction (LVEF) >= institutional normal
+Subjects who have a left ventricular ejection fraction (LVEF) < 50%, as assessed by echocardiogram performed at screening
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
+Shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
+Baseline left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction (LVEF) =< 50%
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
+Patients with known congestive heart failure, symptomatic or left ventricular (LV) ejection fraction < 50% or shortening fraction < 27% are not eligible
+Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
+Ejection fraction < 50% or below the lower limit of the institutional normal range, whichever is lower
+Left ventricular ejection fraction >= 40% or fractional shortening >= 28%
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO), within 2 weeks of the first dose of study treatment
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
+With impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
+History of congestive heart failure and/or an left ventricular ejection fraction (LVEF) < 40%\r\n* Note: patients at increased risk for coronary artery disease or cardiac dysfunction (e.g., > 65 years old [yo], diabetes, history of hypertension, elevated low-density lipoprotein [LDL], first degree relative with coronary artery disease) will undergo full cardiac evaluation and will not be eligible if they demonstrate significant irreversible ischemia on stress thallium or an ejection fraction < 40%
+Ejection fraction >= 50%
+Left ventricular ejection fraction (LVEF) >= 45% corrected
+For patients on Part B: shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
+Patients with a left ventricular ejection fraction of < 45%
+Normal echocardiogram (ECHO) (left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)
+Patients with a left ventricular ejection fraction of < 45%
+Patients who have received prior doxorubicin may not have had more than 320 mg/m^2 total dose and must have a normal left ventricular ejection fraction (LVEF) (>= 45%); (this includes Doxil or other liposomally encapsulated doxorubicin preparations)
+Contraindication to any drug in the chemotherapy regimen, and specifically: LVEF (Left Ventricular Ejection Fraction) < 45% or peripheral neuropathy grade 2
+Left ventricular ejection fraction (LVEF) < 50%;
+Subject has a resting left ventricular ejection fraction (LVEF) of ? 40% obtained by echocardiography.
+Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
+left ventricular ejection fraction (LVEF) of 50% or higher at baseline
+Left Ventricular Shortening Fraction (LVSF) ? 28% confirmed by echocardiogram, or Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or MUGA within 7 days of screening
+Left ventricular ejection fraction (LVEF) >= 55%
+Symptomatic congestive heart failure or evidence of left ventricular dysfunction (ejection fraction < 40%) as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension
+Left ventricular ejection fraction (LVEF) > 50%
+Left ventricular ejection fraction > 40% estimated
+Active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained the left ventricular ejection fraction (LVEF) should exceed 40%
+Patients must not have symptomatic congestive heart failure, coronary artery disease, cardiomyopathy, or uncontrolled arrhythmias; either an echocardiogram or MUGA scan with an ejection fraction >= 45% must be obtained within 14 days prior to registration; (the same scan that was used during induction registration must be used for consolidation registration); the ejection fraction must not have dropped >= 10% from the baseline ejection fraction; if patient has had symptoms suggestive of ischemia or congestive heart failure after that cardiac evaluation was done, a repeat study must be obtained prior to registration
+Left ventricular function 40% or greater
+All subjects must have left ventricular ejection fraction ?50%.
+Left ventricular ejection fraction (LVEF) equal to or greater than the institutional lower limit of normal. LVEF must be evaluated within 28 days prior to beginning study therapy.
+Left ventricular ejection fraction (LVEF) < 40%
+Left ventricular ejection fraction < 45%
+Left ventricular ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
+Have LVEF (left ventricular ejection fraction) <50% at screening
+Left ventricular ejection fraction (LVEF) >= 50% (measured within 28 days of study entry)
+Left ventricular ejection fraction (LVEF) ? 40%
+Cardiac ejection fraction of >= 40% as measured by resting echocardiogram, with no significant pericardial effusion
+Ejection fraction must be >= 50%
+Cardiac ejection fraction >= 50%
+Baseline left ventricular ejection fraction (LVEF) 50%.
+Left ventricular ejection fraction (LVEF) >= 40%
+Human epidermal growth factor receptor 2 (HER-2) status may be pending at initiation of FOLFIRINOX, but must be known prior to starting trastuzumab; if HER-2 is positive, patients must have a left ventricular ejection fraction (LVEF) >= 50%; HER-2 negative patients are not excluded
+A left ventricular ejection fraction (LVEF) must be > 50
+No Symptomatic Congestive Heart Failure (Ejection Fraction EF ? 50%)
+Left ventricular ejection fraction at rest > 40% within 3 months of registration
+Participant's left ventricular ejection fraction is within normal institutional ranges
+ECHO/MUGA demonstrating left ventricular ejection fraction (LVEF)? the lower limit of institutional normal
+Cardiac: left ventricular ejection fraction (LVEF) at rest ? 35% (RIC cohort) or LVEF at rest ? 40% (FIC cohort), or left ventricular shortening fraction (LVFS) ? 25%
+Left ventricular ejection fraction >= 40% or shortening fraction >= 25%
+Left ventricular ejection fraction >= 35% or shortening fraction > 25%
+Left ventricular ejection fraction < 50%.
+Cardiac ejection fraction >= 50%
+Left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction (LVEF) ? 50% or the lower limit of normal (LLN) according to local institution ranges of normality.
+Left ventricular ejection fraction (LVEF) >= 50% for patients enrolling in the HER2 directed therapy arm
+Normal cardiac ejection fraction of > 45%
+Left ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to randomization.
+Left ventricular ejection fraction (LEF) >= 40%
+Ejection fraction > 50% on echocardiogram
+Left ventricular ejection fraction (LVEF) ? 40% within the 21 days prior to randomization
+If cardiac function assessment is clinically indicated or performed: participants will be ineligible if left ventricular ejection fraction (LVEF) is less than normal per institutional guidelines, or < 55%, if the threshold for normal is not otherwise specified by institutional guidelines
+Left ventricular ejection fraction (LVEF) >= 50% performed no more than 4 weeks prior to enrollment
+Cardiac history of CHF requiring treatment or Ejection Fraction less than or equal to 50% or chronic stable angina;
+If the left ventricular ejection fraction (LVEF) < 40, patients will be excluded
+Left ventricular ejection fraction (LVEF) >= 50%
+Ventricular ejection fraction >= 40%
+Left ventricular ejection fraction (LVEF) as assessed by baseline echocardiogram at or above the lower limit of normal
+Left ventricular ejection fraction (LVEF) >= 50%
+PHASE II: Left ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO)
+Left ventricular ejection fraction >= 45%
+Left ventricular ejection fraction >= 50%
+Left ventricular ejection fraction (LVEF) of >= 50%
+Left ventricular ejection fraction < 45% in patients with prior anthracycline use or otherwise at risk for left ventricular systolic dysfunction
+Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by echocardiogram
+Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography
+Resting left ventricular ejection fraction <50% at the time of screening
+Left ventricular ejection fraction (LVEF) >= 45% if patient has known cardiac dysfunction history
+Shortening fraction >= 28%
+Left ventricular ejection fraction >= 50%, as determined by radionuclide ventriculography (RVG) or echocardiogram within 60 days prior to initiation of protocol therapy
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
+Reduced left ventricular ejection fraction (< 50%) or other evidence of cardiac dysfunction as determined by the investigator
+Cardiac ejection fraction < 45%
+Left ventricular ejection fraction (LVEF) >= 50%
+Ejection fraction >= 50% by echocardiogram
+Ejection fraction >= 45%
+Left ventricular ejection fraction < 40% or equivalent shortening fraction < 20% in pediatric patients
+Cardiac ejection fraction >= 45%
+Subjects must have a left ventricular ejection fraction (LVEF) of >= 45%
+Normal left ventricular ejection fraction (LVEF)
+REGISTRATION INCLUSION CRITERIA: Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of > 55% performed no more than 4 weeks prior to randomization
+Baseline left ventricular ejection fraction (LVEF) value less than (<) 55 percent (%)
+Asymptomatic cardiac function or if symptomatic then left ventricular ejection fraction (LVEF) >= 50% and must improve with exercise
+Cardiac ejection fraction > 40%
+Ejection fraction > 40%
+Cardiac ejection fraction >= 40%
+Left ventricular ejection fraction by echocardiogram (ECHO) >= institutional lower limit of normal
+Left ventricular ejection fraction (EF) >= 50%
+Adequate cardiac function as defined as shortening fraction of > 27% OR ejection fraction of > 50%
+Left ventricular ejection fraction > 45% OR
+Shortening fraction > 26%
+Uncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction (LVEF) < 45%
+Resting left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction (LVEF) ? lower limit of normal (LLN) for the Institution
+Patients must have a left ventricular ejection fraction (LVEF) of >= 60% AND/OR
+Left ventricular ejection fraction (LVEF) >/= 50% within 28 days prior to first dose of study drug administration
+Ejection fraction >= 35% (within 6 weeks prior to study enrollment)
+Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 40%
+Cardiac disease with left ventricular ejection fraction of less than 45%
+Left ventricular ejection fraction at least 40%
+The patient has an absence of coexisting medical problems that would significantly increase the risk of the chemotherapy procedure (e.g. poor left ventricular ejection fraction [LVEF<40%])
+Prior left chest wall irradiation or a cumulative anthracycline dose of greater or equal to 300 mg/m^2, unless the ejection fraction or fraction shortening is within normal institutional limits, in which case the patient can be enrolled
+Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrythmias or symptomatic heart disease
+Cardiac ejection fraction <LLN (lower limit of normal)
+Left ventricular ejection fraction of at least 40%
+Patients with a ventricular ejection fraction (=< 30%), or respiratory compromise (FEV1 =< 40%)
+Cardiac left ventricular function with resting ejection fraction of less than institutional lower limit of normal.
+Left ventricular ejection fraction (LVEF) >= 50%
+Ejection fraction (EF) < 35% or uncontrolled cardiac failure
+Ejection fraction (EF) >= 35%
+Left ventricular ejection fraction < 35%
+History of documented congestive heart failure (CHF) or systolic dysfunction (left ventricular ejection fraction [LVEF] < 50%)
+Left ventricular ejection fraction (LVEF) </= institutional lower limit of normal (LLN) by ECHO at the time of transition to this study
+Cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
+Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exercise
+Left ventricular ejection fraction (LVEF) of > 50% by Doppler ultrasound assessment
+Patient must have a normal left ventricular ejection fraction (LVEF) (>= 53%); if a patient has a borderline LVEF (40-52%) they may be considered after consultation with cardiology and study principal investigator (PI) and treated per the guidelines
+Cardiac ejection fraction > 45%
+Left ventricular ejection function < 45%
+Left ventricular ejection fraction (LVEF) >= 45%
+Subjects > age 60 or with clinical signs of heart disease must have ejection fraction >= 45% left ventricular ejection fraction (LVEF) pre-transplant
+Active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained, the left ventricular ejection fraction (LVEF) should exceed 40%
+Pediatric patients: normal left ventricular function with ejection fraction > 55% or shortening fraction >= 27%
+Left ventricular ejection fraction < 50% by ECHO
+Normal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogram
+Cardiac function - left ventricular ejection fraction >= 40%
+Left ventricular ejection fraction (LVEF) >= 40%, however, subjects with a LVEF in the range of 40-49% should have cardiology clearance prior to intervention
+Left ventricular ejection fraction < 35%
+Patients who are receiving trastuzumab must have a left ventricular ejection fraction of >= 50%
+Left ventricular ejection fraction of at least 40% (myeloablative regimen 4, reduced intensity regimen 3) or 30% (nonmyeloablative regimen 2)
+Cardiac ejection fraction < 40%; ejection fraction is required if age > 50 years or there is a history of prior transplant, anthracycline exposure or history of cardiac disease; and poorly controlled hypertension despite multiple antihypertensives
+Participants with a history of chronic heart failure must have cardiac ECHO indicating left ventricular ejection fraction (LVEF) ? 45% within 21 days prior to first dose of study drug
+Adequate cardiac function defined as shortening fraction of >= 27% or ejection fraction >= 45%
+Known ejection fraction < 50%.
+Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise
+Left ventricular ejection fraction < 50%
+The patient has a left ventricular ejection fraction of < 40%
+Patient must have a shortening fraction ? 27% by Echo or an ejection fraction ? 50% by MUGA. Reproductive Function
+Adequate cardiac function defined as shortening fraction of ? 27% by echocardiogram or ejection fraction ? 45% by gated radionuclide study.
+Left ventricular ejection fraction (LVEF) of >= 50%
+Left ventricular ejection fraction <50% as determined by echocardiogram (ECHO) performed at screening or within 30 days prior to C1D1
+Subjects who have a history of, or current evidence of uncontrolled cardiovascular disease or a left ventricular ejection fraction (LVEF) <50%
+Ejection fraction equal or above 40%
+Cardiac: Left ventricular ejection fraction at rest must be > 40%, or shortening fraction > 26%.
+Adequate left ventricular ejection fraction (LVEF) ? 50%
+Adequate heart function with echocardiogram demonstrating ejection fraction >= 45% with no evidence of systolic dysfunction
+Baseline cardiac echocardiogram scan with left ventricular ejection fraction (LVEF) of >= 50%
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)
+Cardiac ejection fraction within normal limits as measured by echocardiogram
+Left ventricular ejection fraction (LVEF) less than 45%
+Cardiac left ventricular ejection fraction (LVEF) >= 35%
+Patients with poor cardiac function defined as an ejection fraction (EF) < 40% are excluded
+Ejection fraction >= 50% by echocardiogram
+Left ventricular ejection fraction >= 45% or fractional shortening >= 28%
+Left ventricular ejection fraction equal or greater than 40%
+Patients must have left-ventricular ejection fraction > 50% at baseline
+Left ventricular ejection fraction (EF) < 50%
+No symptoms of uncontrolled cardiac disease, left ventricular ejection fraction >= 40%
+RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Cardiac function: \r\n* Left ventricular ejection fraction >= 50 by gated radionuclide study OR shortening fraction of >= 27% by echocardiogram\r\n* Patient has no ventricular arrhythmias except for benign premature ventricular contractions\r\n* Patient has a corrected QT (QTc) interval =< 450 ms
+NON-PROGRESSED DIPG (STRATUM 2): Left ventricular ejection fraction >= 50 by gated radionuclide study OR shortening fraction of >= 27% by echocardiogram
+Suboptimal cardiac function as defined by decreased left ventricular ejection fraction < 55% for cohort 1, and < 50% for cohort 2
+Known left ventricular ejection fraction (LVEF) < 50%
+Left Ventricular Ejection Fraction (LVEF) ? 50% Part 1:
+Left ventricular ejection fraction (LVEF) >50% per ECHO or MUGA for patients on the sunitinib arms (Parts 2e and f).
+Left ventricular ejection fraction (LVEF) < 50%
+Left ventricular EF > 40%.
+Left ventricular ejection fraction (LVEF) >= 50 %
+Ejection fraction of >= 50% by radionuclide angiogram
+Left ventricular ejection fraction >= 40% or shortening fraction >= 25%
+If the subject received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within institution's normal limits
+Ejection fraction < 50%
+Adequate cardiac function defined as shortening fraction of >= 27% or ejection fraction >= 45%
+Left ventricular ejection fraction of at least 40-45%
+Cardiac Function a. Patient must have a shortening fraction ? 29% or an ejection fraction ? 40% by ECHO/MUGA.
+LVEF (left ventricular ejection fraction) >= 50%
+No history of serious cardiac arrhythmia or ejection fraction (EF) < 50%
+Left ventricular ejection fraction of >= 55% (or institutional lower normal value)
+Known history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmias
+Known heart failure (ejection fraction [EF] < 40%)
+Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
+Cardiac function: left ventricular ejection fraction (LVEF) >= 40% or shortening fraction (SF) >= 25%
+Left ventricular ejection fraction < 50% as assessed by echocardiogram or radionuclide angiography.
+Ejection fraction of >= 50% by radionuclide angiogram
+Patients with left ventricular ejection fraction (LVEF) < 45% will not be eligible
+Left ventricular ejection fraction (EF) < 50% at baseline
+Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution's lower limit of predicted normal.
+Normal estimated left ventricular ejection fraction and no history of ischemic heart disease requiring revascularization, unless cleared by a cardiologist
+The patient has a baseline corrected QT interval (QTc) >480 ms or left ventricular ejection fraction (LVEF) <50% or less than the lower limit of normal.
+Left ventricular ejection fraction >= 40%
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN)
+Left ventricular ejection fraction (LVEF) ?50% by echocardiogram
+Left ventricular ejection fraction < 50%
+Ejection fraction (EF) >= 45%
+Left ventricular ejection fraction
+Left ventricular ejection fraction < 40 %.
+Baseline left ventricular ejection fraction > or = 50%
+Left ventricular ejection fraction
+Left ventricular ejection fraction (LVEF) < 40%
+Impaired cardiac function defined as left ventricular ejection fraction (LVEF) < 50 % (or below the study site's lower limit of normal) as measured by MUGA or ECHO.
+Left ventricular ejection fraction (LVEF) <40%, as determined by screening echocardiogram (echocardiogram results obtained within 90 days prior to screening are acceptable)
+Left ventricular ejection fraction (LVEF) < 50% by MUGA or echocardiogram
+Adequate cardiac function measured by left ventricular ejection fraction (LVEF) > 50%; if asymptomatic, pre-transplant echocardiogram is adequate; if symptomatic, echocardiogram needs to be repeated
+Adequate cardiac function defined as: left ventricular ejection fraction (LVEF) of either >=50% by ECHO or greater than institutional lower limit of normal (LLN) by echocardiogram (ECHO) (while not receiving medications for cardiac function), corrected QT using Bazett's (QTcB) interval <450 milliseconds (msecs).
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal
+Left ventricular ejection fraction greater than 40%, or shortening fraction greater than or equal to 25%
+Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%
+Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
+Left ventricular ejection fraction (LVEF) ? 40%.
+Left ventricular ejection fraction (LVEF) of at least 55%
+Spirometry with at least 70% of predicted volumes (including FEV1). A left ventricular ejection fraction (LVEF) of 45% or more. All patients will have a screening 2-D Echocardiogram as part of eligibility screening.
+Myocardial infarction (MI) within the previous six months, or patients with left ventricular ejection fraction of less than 45% secondary to a more remote MI.
+Ventricular ejection fraction (VEF) =< 50 % at baseline
+Recipient must have adequate cardiac function with a left ventricular ejection fraction > 40%.
+Left ventricular ejection fraction >= 35% or shortening fraction > 25%, unless cleared by a cardiologist
+Left ventricular ejection fraction > 50% or the institutional LLN within 28 days prior to the first dose of study treatment.
+Shortening fraction of >= 27% by echocardiogram or ejection fraction >= 45% by gated radionuclide study
+Left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
+Patients with a left ventricular ejection fraction less than the institutional lower limit of normal
+Ejection fraction >= 50% by radionuclide evaluation
+Left ventricular ejection fraction (LVEF) >= 40%
+Adequate cardiac function with left ventricular ejection fraction at least 45% on appropriate medical therapy; no uncontrolled arrhythmias or symptomatic cardiac disease
+Ejection fraction < 50% or below the lower limit of the institutional normal range, whichever is lower
+MUGA/Echocardiogram Left Ventricular Ejection Fraction < 50%.
+Cardiac ejection fraction >= 50% without evidence of congestive heart failure (CHF)
+Left ventricular ejection fraction >= 40%
+Cardiac: left ventricular ejection fraction at rest must be greater than 40% or shortening fraction greater than 20%
+Left ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
+Left ventricular ejection fraction (LVEF) >= 40%
+Left ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
+Left ventricular ejection fraction of > 40%
+Left ventricular ejection fraction (LVEF) >= 50%
+Has a pre-treatment transthoracic echocardiography (TTE) showing a calculated left ventricular ejection fraction of less than 50%
+Left ventricular ejection fraction (LVEF) >= 50 %
+Subject has a left ventricular ejection fraction ?45%.
+Abnormal baseline cardiac function defined as an ejection fraction of less than 55%
+Left ventricular ejection fraction >= 35% or shortening fraction > 25%
+Left ventricular ejection fraction (LVEF) >= 35% (within 42 days)
+Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise
+Resting ejection fraction < 50% or fractional shortening < 25%
+History of congestive heart failure and ejection fraction less than 35%
+Subjects should have a normal ejection fraction (per institutional limits), no evidence of cardiac arrhythmias requiring therapy, and a fractional shortening of > 28%
+Left ventricular ejection fraction at rest must be >= 40%, or shortening fraction > 25%
+Left ventricular ejection fraction (LVEF) >= 50%
+Known history of left ventricular ejection fraction (LVEF) ?45% or less than the institutional lower limit of normal;
+Abnormal left ventricular ejection fraction (less than the lower limit of normal for a patient of that age at the treating institution or <45%)
+If in Arm D (doxorubicin and cyclophosphamide), left ventricular ejection fraction (LVEF) >= 50% as measured by echocardiogram (ECHO) within 4 weeks prior to study drug administration
+Normal cardiac function (left ventricular ejection fraction >= 50%)
+Cardiac ejection fraction >= 40%
+Normal cardiac function (left ventricular ejection fraction >= 50%)
+Cardiac ejection fraction > 40%
+Adequate cardiac function defined as an ejection fraction of at least 45%
+Left ventricular ejection fraction > 35%
+Baseline screening echocardiogram (echo) left ventricular ejection fraction (LVEF) =< 50
+Ejection fraction of < 50% (by radionuclide angiogram or echocardiogram) or shortening fraction of < 25% (by echocardiogram)\r\n* Note: for instances where both are reported, and one is below the threshold, the site will have the option to re-measure it centrally at the core lab
+If previously measured, left ventricular ejection fraction (LVEF) >= 50%
+A normal ejection fraction, as defined by the participant’s institution; only limited echocardiograms (ECHOs) will be used as cardiac evaluation; no other tests are allowed; ECHO is to be done only in HLA-A2 positive participants; If ECHO has been done within 30 days prior to randomization and results showing a normal ejection fraction have been obtained prior to randomization, an additional ECHO is not needed at baseline
+Left ventricular ejection fraction > 40%
+Ejection fraction at rest >= 50%
+Left ventricular ejection fraction < 45% and in children-shortening fraction < 26%
+Left ventricular ejection fraction (LVEF) >= 45%
+Ejection fraction of > 47% by radionucleotide angiogram or echocardiogram
+Ejection fraction of > 40% by radionuclide angiogram or echocardiogram
+Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 40%
+Left ventricular ejection fraction < 50% (evaluated by echocardiogram or MUGA)
+Left ventricular ejection fraction (LVEF) >= 40%
+Left ventricular ejection fraction (LVEF) < 50%
+Left ventricular ejection fraction ? 40% or fractional shortening ? 28%
+Cardiac function: ejection fraction > 40%
+Cardiac function: Ejection fraction at rest ? 45%
+Patients must have left ventricular ejection fraction (LVEF) > 45% or within institutional normal limits
+Patients with a history of left ventricular (LV) dysfunction will be still candidates for enrollment in the study if they have documented left ventricular ejection fraction (LVEF) recovery (most recent documented LVEF of 50% or higher) for at least 6 months prior to SPECT regardless of current cardiac medication regimen
+Patients must have normal cardiac ejection fraction
+Participants must have normal cardiac ejection fraction
+Symptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 45%, symptomatic coronary artery disease or symptomatic arrhythmias
+Adequate cardiac function (? NYHA Class II) or normal cardiac function with left ventricular ejection fraction (LVEF) ? 50% at screening.
+Have major abnormalities documented by echocardiography (ECHO) with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction <50%, evaluation based on the institutional lower limit of normal).
+Left ventricular ejection fraction (LVEF) ? 40%
+Significant cardiovascular disease including known left ventricular ejection fraction (LVEF) <40%
+Patient has a cardiac ejection fraction <50%